What Research tells us
These reports are uniquely significant
Imiquimod for the Treatment of Superficial Basal Cell Carcinoma
Imiquimod to Treat Different Cancers of the Epidermis (Report)
Several novel aspects of immunomodulatory treatment with imiquimod and new indications such as selected cases of sclerodermiform BCC and SCC have been described. The texture of the skin at various different body locations may explain the varying sensitivities to imiquimod when facial skin is compared with skin on the extremities.
Topical Imiquimod Clears Invasive Melanoma
Although surgical excision is the recommended treatment of cutaneous melanoma, in some cases the defect following an excision can be quite large or even disfiguring. To minimize the size of the excision site, other treatment modalities should be studied. Imiquimod is an immunomodulating agent that exerts antitumor and antiviral effects. The US Food and Drug Administration has approved imiquimod for treatment of genital warts, actinic keratoses, and superficial basal cell carcinoma.
Dermatologic Dilemmas: The Role of Immune Response Modifiers in Challenging Cases
Imiquimod is package labelled by the U.S. Food and Drug Administration (FDA) for the treatment of genital and anal warts. However, because of its unique mechanism of action, the induction of local cytokine responses, this agent has been and is being studied for its potential utility in a number of other dermatologic conditions, including actinic keratosis (AK), basal cell and squamous cell carcinomas, non-genital human papillomavirus lesions (for example, common, plantar, and periungual warts), as well as molluscum contagiosum and ex-tramammary Paget’s disease.
Subungual Melanoma in Situ Treated with Imiquimod 5% Cream After Conservative Surgery Recurrence
Subungual melanoma is a rare variant of acral lentiginous melanoma that often has a poor prognosis compared with other types of melanoma. The aim of the present study is to report a case of a patient with recurrence of subungual melanoma treated with imiquimod 5%, which presented a total regression of the lesion and no recurrence for 4 years.
Treatment of Nodular Basal Cell Carcinoma with Cryotherapy and Reduced Protocol of Imiquimod
Treatment of Lentigo Maligna (Melanoma in Situ) with the Immune Response Modifier Imiquimod
Surgical excision is the treatment of choice for lentigo maligna (LM), or melanoma in situ. Topical application of imiquimod, a local immune response modifier, is a novel therapeutic approach that leads to LM tumor clearance. This pilot, open-label, nonrandomized study evaluates the efficacy of imiquimod in patients with LM and other systemic problems that make them poor surgical risks.
Rate of Recurrence of Lentigo Maligna Treated with Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision
What is the rate of recurrence of lentigo maligna (LM) in patients treated with neoadjuvant imiquimod, 5%, cream prior to conservatively staged excisions? In this medical record review, 334 patients with 345 LM tumors were treated with off-label imiquimod for a mean of 2.5 months prior to conservatively staged excisions. The recurrence rate was 3.9% with a mean time to recurrence of 4.3 years and a mean follow-up of 5.5 years. Meaning: Eighty-one percent of patients treated with imiquimod prior to conservatively staged excisions had clearance of LM after 1 stage with recurrence rates comparable with other excisional techniques.